Japanese Journal of Ophthalmology最新文献

{"title":"Corrected gestational age-specific prediction models for identifying treatment-requiring retinopathy of prematurity.","authors":"Sao Sugimoto, Masako Nagahara, Kentaro Hayashi, Takuya Kuriyama, Han Peng Zhou, Gen Mihara, Kosuke Nakajima, Takashi Ueta, Taku Toyama","doi":"10.1007/s10384-026-01403-7","DOIUrl":"https://doi.org/10.1007/s10384-026-01403-7","url":null,"abstract":"<p><strong>Purpose: </strong>To develop and validate time-updated, corrected gestational age (CGA)-specific prediction models for identifying treatment-requiring retinopathy of prematurity (ROP) using routinely available systemic factors, and to assess longitudinal changes in predictor combinations and model performance with advancing CGA.</p><p><strong>Study design: </strong>Retrospective cohort study.</p><p><strong>Methods: </strong>Preterm infants who met institutional ROP screening criteria from a single tertiary center were included, excluding those with aggressive ROP. Multivariable logistic regression models were independently developed at CGA 28, 30, 32, and 34 weeks using routinely available systemic variables summarized from birth to each CGA. For each CGA-specific analysis, infants treated before the target CGA were excluded. Exhaustive subset selection based on the Akaike information criterion identified CGA-specific optimal predictor sets. Model performance was evaluated using stratified five-fold cross-validation with out-of-fold predictions, and discrimination was assessed by the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Predictor combinations selected by the optimal models differed across CGAs, indicating longitudinal changes in the predictive relevance of systemic factors. Growth-related and inflammatory indices were repeatedly selected, while overall predictor composition evolved with advancing CGA. Discrimination improved at later CGAs, with cross-validated AUCs of 0.650, 0.716, 0.809, and 0.842 at CGA 28, 30, 32, and 34 weeks, respectively.</p><p><strong>Conclusion: </strong>These findings suggest that CGA-specific prediction models may help characterize the evolving risk of treatment-requiring ROP. However, prospective multicenter validation and further refinement are required before clinical application.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and safety of a fixed-dose combination of 0.4% ripasudil and 0.1% brimonidine in the management of uveitic glaucoma.","authors":"Sentaro Kusuhara, Wataru Matsumiya, Sotaro Mori, Mari Sakamoto, Yuko Yamada-Nakanishi, Makoto Nakamura","doi":"10.1007/s10384-026-01397-2","DOIUrl":"https://doi.org/10.1007/s10384-026-01397-2","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the real-world use, treatment outcomes, and tolerability of the fixed-dose combination of ripasudil 0.4% and brimonidine 0.1% (RBFC) eye drops in patients with uveitic glaucoma (UG).</p><p><strong>Study design: </strong>Single-center retrospective case series.</p><p><strong>Methods: </strong>Medical records of 39 eyes with open-angle UG treated with RBFC were reviewed. The outcome measures included changes in intraocular pressure (IOP) and glaucoma drug score (GDS) at 12 months, the proportion of eyes with an IOP reduction of ≥2 mmHg at 12 months, the relationship between the duration of UG and the change in IOP at 12 months, changes in IOP in eyes switched from ripasudil plus brimonidine, and adverse events.</p><p><strong>Results: </strong>The median IOP significantly decreased from 19 mmHg at baseline to 14 mmHg at 12 months (p < 0.001), while the median GDS showed no significant change, from 3 at baseline to 4 at 12 months (p = 0.562). At 12 months, 64% of eyes achieved an IOP reduction of ≥2 mmHg. A positive correlation was observed between the duration of UG and the change in IOP at 12 months (rho = 0.539, p < 0.01). In the subgroup analysis restricted to eyes switched from ripasudil plus brimonidine eye drops to RBFC, IOP showed a decreasing trend (p = 0.057). No drug-related adverse events were observed, except for transient conjunctival hyperemia.</p><p><strong>Conclusion: </strong>This real-world study in patients with UG showed that RBFC achieves effective IOP control while reducing treatment burden, with good tolerability, supporting its continued use in UG management.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute retinal necrosis: an assessment of vitreous and retinal detachment.","authors":"Yosuke Arai, Hideo Akiyama, Shunsuke Tokui, Kazuma Saito, Daisuke Todokoro","doi":"10.1007/s10384-026-01396-3","DOIUrl":"10.1007/s10384-026-01396-3","url":null,"abstract":"<p><strong>Purpose: </strong>To examine the relationship between posterior vitreous changes and retinal detachment (RD) associated with acute retinal necrosis (ARN).</p><p><strong>Study design: </strong>Retrospective, consecutive case study.</p><p><strong>Methods: </strong>This study evaluated the clinical findings for 32 eyes of 29 patients (12 women, 17 men) diagnosed with ARN, with the posterior vitreous condition monitored by swept-source optical coherence tomography (SS-OCT). The causative virus, incidence of RD, and relationship between the development of RD and final visual acuity were investigated. Patients were checked for posterior vitreous detachment (PVD) from the initial visit to the last SS-OCT observation.</p><p><strong>Results: </strong>Varicella-zoster virus caused 67% of the ARN cases, with RD developing in 66% of the cases, and proliferative vitreoretinopathy (PVR) in 90% at onset or at recurrence. Silicone oil could not be removed in 38% of the cases with RD. Final best-corrected visual acuity was significantly worse in the RD (+) group than in the RD (-) group (median logMAR 1.02 vs. 0.16, p = 0.04). PVD occurred in 20 of 21 eyes without PVD at the initial examination, with 18 of these 20 eyes developing RD (90%). PVD occurred at an average of 45.8 ± 32.1 days after the initial examination, with 85% of the cases developing PVD within 3 months.</p><p><strong>Conclusions: </strong>The visual prognosis of ARN complicated by RD is poor. PVD is involved in the development of RD and is often associated with PVR, which itself is refractory.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Clinical practice guideline for anterior segment dysgenesis.","authors":"","doi":"10.1007/s10384-026-01385-6","DOIUrl":"10.1007/s10384-026-01385-6","url":null,"abstract":"","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"1037"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148375658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study.","authors":"Hitoshi Ishikawa, Koji Oka, Hiroshi Inoue","doi":"10.1007/s10384-026-01340-5","DOIUrl":"10.1007/s10384-026-01340-5","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the 6-month efficacy and safety of oxymetazoline hydrochloride ophthalmic solution 0.1% (OMZ 0.1%) versus placebo for acquired blepharoptosis.</p><p><strong>Study design: </strong>A phase 3, randomized, double-masked, parallel-group, multicenter study conducted in Japan.</p><p><strong>Methods: </strong>Patients were randomized 1:1:1 to OMZ 0.1%, once daily (QD) or twice daily (BID), or placebo. Patients received OMZ 0.1% for 6 months. Patients in the placebo group were randomized after 3 months (Treatment Period 1) to OMZ 0.1%, either QD or BID, for the remaining 3 months (Treatment Period 2). The primary efficacy endpoint was the marginal reflex distance-1 (MRD-1) change from baseline to Day 14 (2 hours after the morning drop) with OMZ 0.1% QD or BID versus placebo. Adverse events and adverse drug reactions (ADRs) were recorded.</p><p><strong>Results: </strong>Overall, baseline MRD-1 (standard deviation) of 336 patients analyzed (n=112 per group) was 1.31 (0.83) mm (Day 0). MRD-1 change from baseline to Day 14 (2 hours after the morning drop) was 1.09 (0.07), 0.93 (0.07), and 0.50 (0.07) mm, with OMZ 0.1% QD, BID, and placebo, respectively. There was a statistically significant difference in the least squares mean (standard error) MRD-1 change versus placebo with OMZ 0.1% QD (0.59 [0.10] mm; 95% CI 0.38, 0.79) and OMZ 0.1% BID (0.43 [0.10] mm; 95% CI 0.23, 0.64) (both p<0.05). All ADRs related to the study drug were mild.</p><p><strong>Conclusion: </strong>Fourteen days of OMZ 0.1% treatment significantly increased MRD-1 versus placebo. There was no loss of effect after 6 months of treatment and no significant safety concerns.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"820-829"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical performance of the multiplex solid-phase \"Direct Strip PCR\" for infectious uveitis: a multicenter diagnostic accuracy study.","authors":"Satoko Nakano, Sunao Sugita, Hiroshi Takase, Yasuhiro Tomaru, Daisuke Todokoro, Yumi Hasegawa, Yasuhiro Ikeda, Go Mawatari, Chie Sotozono, Kenji Nagata, Kaoru Araki-Sasaki, Suguru Nakagawa, Yoshiaki Kiuchi, Kaori Mitoma, Nobuyo Yawata, Takehiro Hariya, Eiichi Uchio, Tomoko Tsukahara-Kawamura, Hidenori Inoue, Koji Toriyama, Sentaro Kusuhara, Wataru Matsumiya, Nobuyuki Ohguro, Hisashi Mashimo, Ken Fukuda, Waka Ishida, Mariko Egawa, Kei Nakai, Masakazu Morioka, Atsushi Hayashi, Tomoko Nakamura, Yoshihiko Usui, Hiroshi Goto, Ryohei Nejima, Kazunori Miyata, Kenichi Namba, Keitaro Hase, Annabelle A Okada, Hiroshi Keino, Nobuhisa Mizuki, Masaki Takeuchi, Dai Miyazaki, Kunihiro Kiyosaki, Reiko Kinouchi, Ryoji Yanai, Sho-Hei Uchi, Shigeko Yashiro, Rie Tanaka, Aika Tsutsui, Takashi Suzuki, Yukiko Umeki, Takaaki Yahiro, Akane Sonezaki, Takashi Matsumoto, Tetsuji Ohyama, Masae Kuranari, Naoto Uemura, Yuichi Hori, Atsunobu Takeda, Toshiaki Kubota, Toshikatsu Kaburaki, Koh-Hei Sonoda, Manabu Mochizuki","doi":"10.1007/s10384-026-01343-2","DOIUrl":"10.1007/s10384-026-01343-2","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical performance of \"Direct Strip PCR,\" a multiplex solid-phase real-time polymerase chain reaction (PCR) kit, for diagnosing infectious uveitis.</p><p><strong>Study design: </strong>Multicenter, prospective, diagnostic accuracy study METHODS: We analyzed 475 ocular-fluid samples (336 aqueous humor and 139 vitreous fluid) from 29 sites in Japan. Direct Strip PCR, an IVD-grade multiplex real-time PCR kit targeting HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HTLV-1, Toxoplasma gondii, and Treponema pallidum requiring no DNA extraction and incorporating internal controls, was compared with quantitative PCR (qPCR) for concordance and DNA copy-number correlation.</p><p><strong>Results: </strong>All 9 of the target pathogens were detected. Direct Strip PCR showed excellent agreement with qPCR, with percent positive agreement (PPA), percent negative agreement (PNA), and percent overall agreement (POA) in aqueous humor of 98.0%, 99.2%, and 98.5%, respectively, and in vitreous fluid of 95.7%, 97.1%, and 96.4%, respectively, indicating high concordance for positive and negative results. All the values exceeded predefined 90% thresholds agreed upon with the Pharmaceuticals and Medical Devices Agency, meeting the required performance criteria. Discordant results were infrequent (10/4275 targets) and involved low-copy samples near the detection limit. The DNA copy numbers correlated strongly between the methods (r = 0.948-0.996). No adverse events were reported.</p><p><strong>Conclusion: </strong>Direct Strip PCR demonstrated high concordance with qPCR, reliably detected major pathogens of infectious uveitis, and yielded quantitative results that correlated with the qPCR results, supporting disease monitoring. Its solid-phase, extraction-free, and per-run calibration-free format provides a practical basis for regulatory submissions and global dissemination of multiplex PCR.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"966-982"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147592292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paired-eye comparison of photocoagulation versus intravitreal bevacizumab for retinopathy of prematurity: long-term visual, refractive, and ocular biometric outcomes at corrected ages 1, 5, and 9 years.","authors":"Yoshimi Fukushima, Machi Takata, Akiteru Kawahara, Hideki Chuman, Nobuhisa Naoi, Yasuhiro Ikeda","doi":"10.1007/s10384-026-01359-8","DOIUrl":"10.1007/s10384-026-01359-8","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate long-term outcomes of photocoagulation (PC) and intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).</p><p><strong>Study design: </strong>Retrospective paired-eye comparison.</p><p><strong>Methods: </strong>Twenty-one patients (42 eyes) treated for ROP between 2009-2010 were included. In each subject, one eye received PC and the fellow IVB. Visual acuity (VA), refraction (spherical equivalent [SE], cylinder power [CP], corneal astigmatism [CA]), and ocular biometry (corneal curvature radius, anterior chamber depth [ACD], lens thickness [LT], and axial length [AL]) were assessed at corrected ages of 1, 5, and 9 years. Cross-sectional differences were analyzed using the Wilcoxon signed-rank test, with Bonferroni correction applied at 9 years. Annual rates of change were evaluated using a linear mixed-effects model (LMM). Inter-treatment differences were assessed using Spearman correlation analysis.</p><p><strong>Results: </strong>At 9 years, PC-treated eyes showed significantly worse VA, greater myopia, and shorter AL (all p < 0.05). ACD was deeper in IVB-treated eyes, while CP and CA were greater in PC-treated eyes. LMM revealed a significantly faster progression of myopia and CP in PC-treated eyes. Conversely, the annual rates of ACD deepening and LT thinning were significantly faster in IVB-treated eyes, whereas no significant differences were observed for VA or AL. Inter-treatment differences in SE were significantly correlated with AL differences, whereas VA differences were correlated with ACD.</p><p><strong>Conclusion: </strong>IVB-treated eyes showed better VA, less myopia, and more favorable refractive and biometric parameters. SE differences were associated with AL, whereas VA differences were associated with ACD, indicating distinct structural mechanisms.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"773-784"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corneal biomechanical and tomographic outcomes following accelerated cross-linking in keratoconus: a focus on cone localization.","authors":"Yonca Asfuroğlu, Emine Esra Karaca, Döndü Melek Ulusoy, Özlem Evren Kemer","doi":"10.1007/s10384-026-01338-z","DOIUrl":"10.1007/s10384-026-01338-z","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the biomechanical and tomographic characteristics of keratoconic corneas undergoing accelerated cross-linking (CXL) for over one year and to assess the impact of cone localization on postoperative biomechanical behavior.</p><p><strong>Study design: </strong>Prospective-comparative.</p><p><strong>Methods: </strong>This study included 68 eyes of 68 patients with progressive keratoconus. Based on cone location, the patients were divided into two groups: group 1 (central cone; 34 eyes) and group 2 (paracentral cone; 34 eyes). Scheimpflug imaging was used to assess the corneal thickness, anterior and posterior Kmean, Kmax, and astigmatism. The Ocular Response Analyzer (ORA) measures corneal compensated intraocular pressure (IOPcc), Goldmann-correlated pressure (IOPg), corneal hysteresis (CH), and corneal resistance factor (CRF). All the baseline measurements were repeated at 1, 6, and 12 months. Demarcation line (DL) depth was assessed at 1 month using anterior segment optical coherence tomography. Best corrected visual acuity was recorded at each visit.</p><p><strong>Results: </strong>At 1year, anterior Kmean, posterior Kmean and Kmax showed significant reductions (p < 0.01). No significant differences in CH or CRF changes were found between the central and peripheral cones (p = 0.22, p = 0.33). Visual improvement and reduction in spherical equivalent were greater in the central cone group (p = 0.03, p = 0.03). DL depth correlated positively with CH and CRF at 1 month (p = 0.02, p = 0.008), but not at 1 year.</p><p><strong>Conclusion: </strong>Accelerated CXL improves corneal shape, but may not produce detectable changes in ORA-derived biomechanics. Regional stiffening may not be captured by global indices, and the cone location appears to be more influential on visual recovery than biomechanical parameters.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"796-803"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147348313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical efficacy, safety, and success factors of botulinum toxin type A in the treatment of acute acquired comitant esotropia.","authors":"Makiko Ui, Toshiaki Goseki, Ayumi Watanabe, Kinue Fueki, Yuko Komiya, Risako Hasunuma, Noriko Tsutsumi, Hiroki Yoshida","doi":"10.1007/s10384-026-01331-6","DOIUrl":"10.1007/s10384-026-01331-6","url":null,"abstract":"<p><strong>Purpose: </strong>Acute acquired comitant esotropia (AACE) is an increasingly reported form of esotropia, possibly linked to the rising use of digital devices. Botulinum toxin type A (BTXA) has emerged as a minimally invasive treatment alternative to surgery, particularly for patients with diplopia. We aimed to investigate the efficacy and safety of BTXA injections in treating AACE while identifying factors contributing to successful treatment outcomes.</p><p><strong>Study design: </strong>A retrospective, single-center study.</p><p><strong>Methods: </strong>This study retrospectively evaluated 228 patients with AACE who received BTXA injections at a single center. Treatment outcomes, adverse events, and factors influencing success were analyzed. Successful outcomes were defined as either the absence of diplopia in the primary position or an angle of deviation of ≤10 prism diopters from orthotropia, both evaluated at more than 6 months after the last injection.</p><p><strong>Results: </strong>The average patient age was 30.9 years, and 52% achieved successful outcomes. Transient adverse events, including blepharoptosis (24%) and hypertropia (16%), were observed. The study found that shorter duration from onset to treatment (P = 0.018) and post-treatment overcorrection (P = 0.0073) were associated with higher success rates. Although some patients required additional treatment or surgery due to recurrence, BTXA was an effective intervention for AACE, with a significant improvement in eye alignment and stereopsis.</p><p><strong>Conclusion: </strong>Early intervention with BTXA is crucial for successful outcomes and offers a safe, less invasive alternative to traditional strabismus surgery.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"907-914"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452831/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146165463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year outcomes of pneumatic displacement for submacular hemorrhage secondary to neovascular age-related macular degeneration.","authors":"Kanako Itagaki, Ryo Mukai, Junichiro Honjo, Tetsuju Sekiryu","doi":"10.1007/s10384-026-01336-1","DOIUrl":"10.1007/s10384-026-01336-1","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the one-year outcomes of pneumatic displacement for submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD). We compared cases of polypoidal choroidal vasculopathy (PCV) and non-PCV.</p><p><strong>Study design: </strong>A retrospective observational study.</p><p><strong>Methods: </strong>We reviewed the medical records of 76 eyes of 74 patients with SMH secondary to nAMD who underwent pneumatic displacement as initial treatment. The primary outcomes were best-corrected visual acuity (BCVA), complications, and additional treatment.</p><p><strong>Results: </strong>We examined 54 eyes with PCV and 22 eyes with non- PCV. Approximately 0.5 mL of 100% sulfur hexafluoride (SF₆) gas was injected into the vitreous cavity. After pneumatic displacement, 19 eyes (25%) underwent vitrectomy for complications such as vitreous hemorrhage or retinal detachment. Additionally, 95% of eyes that underwent vitrectomy had hemorrhage extending beyond the arcade vessels at baseline. During the 12 months, the average number of anti-vascular endothelial growth factor (VEGF) injections was 7.0±3.6 in PCV cases and 7.0±3.3 in non-PCV cases (P=0.74). The mean BCVA at 12 months improved from 0.77±0.44 to 0.42±0.45 in PCV cases (P<0.01) and from 1.13±0.51 to 0.88±0.59 in non-PCV cases (P=0.01). The PCV group had better BCVA than the non-PCV group at both time points (P<0.01). In the previously treated group, 100% of non-PCV cases had worsened visual acuity compared to pre-onset SMH, while 62% of PCV cases maintained pre-onset visual acuity (P<0.01).</p><p><strong>Conclusion: </strong>Pneumatic displacement resulted in superior visual outcomes in the PCV group compared to the non-PCV group for submacular hemorrhage secondary to nAMD. .</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"876-885"},"PeriodicalIF":2.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147289863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}